BU/melphalan and auto-SCT in AML patients in first CR: a Gruppo Italiano Trapianto di Midollo Osseo (GITMO) retrospective study

R. M. Lemoli, A. D'addio, G. Marotta, L. Pezzullo, E. Zuffa, M. Montanari, A. De Vivo, A. Bonini, P. Galieni, A. M. Carella, S. Guidi, M. Michieli, A. Olivieri, A. Bosi

Research output: Contribution to journalArticlepeer-review

Abstract

AML patients (total 129; median age 50 years; range 16-72) in first CR received BU and melphalan (BU/Mel) as conditioning regimen before auto-SCT. In all, 82 patients (63.6%) received PBSCs and 47 patients (36.4%) received BM cells. The distribution of cytogenetic categories was conventionally defined as favorable (15.5%), intermediate (60.1%) and unfavorable (24.3%). With a median follow-up of 31 months, the 8-year projected OS and disease-free survival (DFS) was 62 and 56% for the whole population, respectively. The relapse rate was 46% and the non-relapse mortality was 4.65%. Although PBSC transplantation led to a faster hematological recovery than BM transplantation, in univariate analysis the stem cell source, cytogenetics and different BU formulations did not significantly affect OS and DFS, whereas age and the number of post-remission chemotherapy cycles did have a significant effect on the clinical outcome. Multivariate analysis identified age

Original languageEnglish
Pages (from-to)640-646
Number of pages7
JournalBone Marrow Transplantation
Volume45
Issue number4
DOIs
Publication statusPublished - Apr 2010

Keywords

  • AML
  • Auto-SCT
  • Conditioning regimen
  • CR

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint

Dive into the research topics of 'BU/melphalan and auto-SCT in AML patients in first CR: a Gruppo Italiano Trapianto di Midollo Osseo (GITMO) retrospective study'. Together they form a unique fingerprint.

Cite this